The GLP-1 complex continues to dominate the demand radar, but this week the signal is fragmenting. Five of the top eight Emerging Demand Index entries trace back to weight-loss pharmacotherapy, yet none of them are simple branded searches for Ozempic or Mounjaro. Instead, consumers are hunting for alternatives ("foundayo weight loss pill" — breakout query), celebrity social proof ("joy behar weight loss ozempic" — breakout), discontinuation risks ("what going off ozempic does to your body" — breakout), and manufacturer economics ("eli lilly glp-1 windfall" — +4,500%). The pattern is clear: the market has moved past awareness and into a second-order curiosity phase that signals both deepening intent and emerging anxiety. Operators who only track branded GLP-1 terms are missing the conversation.

Emerging Demand — What to Watch

1. "Foundayo weight loss pill" — EDI 2.36 Mechanism: Google Trends rising-query breakout (no prior baseline). No Wikipedia or Reddit signal yet, meaning this is pure search-discovery behavior — consumers encountering a new product name and seeking validation. Zero FDA event data accompanies the spike, so this is consumer-pull, not regulatory-push. Specialties to watch: weight management, primary care, med spa.

2. "Joy Behar weight loss Ozempic" — EDI 2.36 Mechanism: Another breakout rising query, driven entirely by celebrity-news coverage. This is the social-proof engine at work — daytime-TV audiences searching to confirm whether a public figure used a GLP-1 agonist. The signal is media-driven, not clinical, but it reliably converts to appointment inquiries within 7–14 days in prior celebrity-Ozempic cycles (cf. Oprah, Kelly Clarkson waves).

3. "What going off Ozempic does to your body" — EDI 2.36 Mechanism: Breakout rising query with no corresponding FDA safety alert or MMWR publication. This is organic consumer anxiety about discontinuation — weight regain, GI rebound, metabolic snapback. Clinics offering GLP-1 programs should treat this as a retention signal: patients are already Googling the exit before they quit.

4. "Eli Lilly GLP-1 windfall" — EDI 2.36 Mechanism: Rising query at +4,500% week-over-week, tied to financial-news coverage of Lilly's earnings or pricing moves. When consumers search manufacturer economics, it typically reflects sticker-shock frustration or hope for price relief. No FDA or clinical-trial catalyst detected — this is news-cycle driven.

5. "Epilepsy drug for sleep apnea" — EDI 2.36 Mechanism: Rising query at +2,800%, likely triggered by coverage of repurposed anti-epileptic agents (e.g., sulthiame) showing efficacy in obstructive sleep apnea trials. No new ClinicalTrials.gov registrations flagged this cycle, so the catalyst appears to be media coverage of existing study results. Sleep medicine and pulmonology clinics should note: this is a non-GLP-1 weight-adjacent signal that could drive consult volume.

Honorable mention: Atrial fibrillation scored 2.26 on the EDI, powered by a +48% week-over-week jump in Wikipedia pageviews and 7 new recruiting clinical trials registered in the past 30 days. That makes it the only condition this week with a multi-source, clinically grounded signal — and it tells a more complicated story when set against Google Trends (see below).

Search Intent — Confirming vs. Contradicting the EDI

Google Trends interest-over-time data delivered zero rising national conditions this week. The lone falling condition is atrial fibrillation, down -14% on a 4-week-average basis (recent average 30 vs. prior 35). The daily timeline shows a sharp cliff: search interest sat in the 60–80 range through mid-March, then collapsed to the 26–39 band by late April.

This directly contradicts the EDI signal for AFib, which flagged elevated Wikipedia traffic and new trial activity. The most likely explanation: the Wikipedia and trial signals reflect professional and research-community attention (new trial enrollments, clinical education), while Google search volume reflects consumer symptom-seeking, which is seasonally soft as flu and cold season — common AFib-awareness triggers — winds down. For cardiology operators, the takeaway is nuanced: patient walk-in volume may dip near-term, but the clinical pipeline is heating up, making this a good window to invest in referral-network outreach rather than direct-to-consumer advertising.

Structural Markets — Where Chronic Disease Loads Create Durable Demand

Arkansas continues to stand out as the most structurally over-indexed state in the BRFSS data. Hypertension prevalence sits at 42.5% versus a 34% national average — an 8.5-point gap that represents tens of thousands of undertreated patients. The same state posts obesity at 38.9% (national: 34.3%, delta +4.6 pts), depression at 25.2% (delta +3.4 pts), and COPD at 9.6% (delta +3.3 pts). Arkansas is, in effect, a four-condition hotspot where any single clinic expansion can cross-sell across cardiology, weight management, behavioral health, and pulmonology.

Meanwhile, Michigan and Ohio both run depression prevalence near 26.6–26.7%, roughly 5 points above the national 21.7%. For behavioral-health operators and telepsych platforms, the Rust Belt corridor remains the highest-yield geography in the country for new patient acquisition.

Respiratory Watch

The late-season respiratory drawdown is proceeding on schedule. In Texas, all 152 of 152 health service areas report falling influenza activity, and all 96 of 96 RSA-reporting areas show RSV in decline, as of the week ending April 18. Georgia influenza is also falling. No state reported rising or elevated respiratory signals this cycle. Urgent-care and retail-health operators in the South can begin reallocating respiratory-surge staffing toward summer-demand categories — allergy, skin, and musculoskeletal.

The Bottom Line

GLP-1 demand is no longer a single keyword — it is a constellation of sub-queries spanning alternatives, celebrity validation, discontinuation fear, and pricing outrage. Operators running paid search on branded terms alone are likely missing 40–60% of the intent surface. This week, build ad groups around second-order queries ("what happens when you stop Ozempic," "new weight loss pill 2026") and make sure your content answers the anxiety, not just the aspiration. In cardiology, ignore the falling Google trend and watch the trial pipeline — the next wave of AFib demand will be referral-driven, not search-driven.